CG Oncology, Inc. - Expanded Access Programs

Expanded Access Intelligence

Official Statements

Score contribution: 100 — 2 supporting sources.

Score 1002 references

Featured Reference

Development Pipeline | CG0070 | CG OncologyOpens in new window

“Additionally, we’ve initiated an Expanded Access Program for cretostimogene in the U.S. for patients with NMIBC who are unresponsive to BCG and meet certain program eligibility criteria.”

PRESENTATION TITLESource

“# Cretostimogene Expanded Access Program (EAP) Program Objectives • Available for a broader range of patients with CIS-containing BCG-UR NMIBC • Prioritize geographically and ethnically diverse population of real-world patients • CG Oncology will provide supply of cretostimogene”

EAP Related Articles from Sponsor

Score contribution: 80 — 7 supporting sources.

Score 807 references

Featured Reference

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec | CG OncologyOpens in new window

CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that it has initiated an Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette-Guerin (BCG) and meet certain program eligibility criteria. The first patient has been dosed in the EAP and enrollment in the study is ongoing.

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates | CG OncologySource

Initiated and dosed first patient in Expanded Access Program for Cretostimogene Grenadenorepvec; Enrollment ongoing

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024 | CG OncologySource

Additionally, we have initiated an Expanded Access Program for cretostimogene in North America for patients who are unresponsive to BCG and meet certain program eligibility requirements.

Abstracts and Presentations - CG Oncology |Source

[Expanded Access Program of Cretostimogene Grenadenorepvec in Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin](https://cgoncology.com/wp-content/uploads/2025/02/Trial-in-Progress-Cretostimogene-Grenadenorepvec-EAP-in-HR-BCG-UR-NMIBC-1.pdf) (pdf)

CG Oncology to Present Results on Cretostimogene ...Source

The Cretostimogene Grenadenorepvec Expanded Access Program in Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | CG OncologySource

Additionally, we have initiated an Expanded Access Program for cretostimogene in North America for patients who are unresponsive to BCG and meet certain program eligibility requirements.

Active EAPs on ClinicalTrials.gov

Score contribution: 60 — 1 supporting sources.

Score 601 references

Featured Reference

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCGOpens in new window

Conditions: Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Urologic Cancer, Bladder Cancer

Partner with Right2Hope

Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.

Talk to Our Team Explore Programs